EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...

There’s trouble brewing beneath the GLP-1 buzz. As Americans embrace blockbuster weight-loss drugs like Ozempic and Wegovy in ...

Curating evidence-based lifestyle recommendations is key to achieving ideal cardiometabolic health in patients with obesity, as there is no “one-size-fits-all,” according to a presentation.At World ...

Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...

Danish pharmaceutical giant Novo Nordisk has introduced its type 2 diabetes treatment, Ozempic, in India. Positioned as a ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this ...

Today, the European Medicines Agency’s Committee for Medicinal Products for Human Use, CHMP, issued a positive opinion for a ...

The pharmaceutical giant Eli Lilly has once again raised the bar in the highly competitive obesity treatment market. New clinical trial data for its experime ...

A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

The company also said earlier this week it will drop $6 billion on a new manufacturing facility in Huntsville, Alabama.